An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48. https://doi.org/10.3322/caac.21763.

Article  PubMed  Google Scholar 

Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015–2019. Neuro Oncol. 2022;24:v1–95. https://doi.org/10.1093/neuonc/noac202.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wirsching HG, Galanis E, Weller M. Glioblastoma. Handb Clin Neurol. 2016;134:381–97. https://doi.org/10.1016/b978-0-12-802997-8.00023-2.

Article  PubMed  Google Scholar 

Miller KD, Ostrom QT, Kruchko C, Patil N, Tihan T, Cioffi G, et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 2021;71:381–406. https://doi.org/10.3322/caac.21693.

Article  PubMed  Google Scholar 

Johnson DR, O’Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol. 2012;107:359–64. https://doi.org/10.1007/s11060-011-0749-4.

Article  CAS  PubMed  Google Scholar 

Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;344:1396–401. https://doi.org/10.1126/science.1254257.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tomaszewski W, Sanchez-Perez L, Gajewski TF, Sampson JH. Brain Tumor Microenvironment and Host State: Implications for Immunotherapy. Clin Cancer Res. 2019;25:4202–10. https://doi.org/10.1158/1078-0432.ccr-18-1627.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chongsathidkiet P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH, et al. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med. 2018;24:1459–68. https://doi.org/10.1038/s41591-018-0135-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, et al. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro Oncol. 2018;20:184–91. https://doi.org/10.1093/neuonc/nox175.

Article  CAS  PubMed  Google Scholar 

Taqi AM, Abdurrahman MB, Yakubu AM, Fleming AF. Regression of Hodgkin’s disease after measles. Lancet. 1981;317:1112. https://doi.org/10.1016/s0140-6736(81)92286-8.

Article  Google Scholar 

Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther. 2007;15:651–9. https://doi.org/10.1038/sj.mt.6300108.

Article  CAS  PubMed  Google Scholar 

Mondal M, Guo J, He P, Zhou D. Recent advances of oncolytic virus in cancer therapy. Hum Vaccin Immunother. 2020;16:2389–402. https://doi.org/10.1080/21645515.2020.1723363.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Achard C, Surendran A, Wedge ME, Ungerechts G, Bell J, Ilkow CS. Lighting a fire in the tumor microenvironment using oncolytic immunotherapy. EBioMedicine. 2018;31:17–24. https://doi.org/10.1016/j.ebiom.2018.04.020.

Article  PubMed  PubMed Central  Google Scholar 

• Palanivelu L, Liu CH, Lin LT. Immunogenic cell death: the cornerstone of oncolytic viro-immunotherapy. Front Immunol. 2022;13:1038226. https://doi.org/10.3389/fimmu.2022.1038226. This is an informative review detailing the complex changes that oncolytic virotherapy can induce in the tumor microenvironment and the responding immune system. Understanding this interplay is critical for determining the optimal choice of virus and combinatorial strategy such as immune checkpoint inhibitors or CAR T/NK cells.

Article  CAS  PubMed  Google Scholar 

Donnelly OG, Errington-Mais F, Steele L, Hadac E, Jennings V, Scott K, et al. Measles virus causes immunogenic cell death in human melanoma. Gene Ther. 2013;20:7–15. https://doi.org/10.1038/gt.2011.205.

Article  CAS  PubMed  Google Scholar 

Sooreshjani M, Tripathi S, Dussold C, Najem H, de Groot J, Lukas RV, et al. The use of targeted cytokines as cancer therapeutics in glioblastoma. Cancers (Basel). 2023;15:3739. https://doi.org/10.3390/cancers15143739.

Article  CAS  PubMed  Google Scholar 

Ghasemi Darestani N, Gilmanova AI, Al-Gazally ME, Zekiy AO, Ansari MJ, Zabibah RS, et al. Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment. Cell Commun Signal. 2023;21:43. https://doi.org/10.1186/s12964-022-01012-0.

Article  PubMed  PubMed Central  Google Scholar 

Hennessy C, McKernan DP. Anti-viral pattern recognition receptors as therapeutic targets. Cells. 2021;10:2258. https://doi.org/10.3390/cells10092258.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gong T, Liu L, Jiang W, Zhou R. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol. 2020;20:95–112. https://doi.org/10.1038/s41577-019-0215-7.

Article  CAS  PubMed  Google Scholar 

Sharma SK, Naidu G. The role of danger-associated molecular patterns (DAMPs) in trauma and infections. J Thorac Dis. 2016;8:1406–9. https://doi.org/10.21037/jtd.2016.05.22.

Article  PubMed  PubMed Central  Google Scholar 

Yu R, Zhu B, Chen D. Type I interferon-mediated tumor immunity and its role in immunotherapy. Cell Mol Life Sci. 2022;79:191. https://doi.org/10.1007/s00018-022-04219-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bencze D, Fekete T, Pázmándi K. Type I interferon production of plasmacytoid dendritic cells under control. Int J Mol Sci. 2021;22:4190. https://doi.org/10.3390/ijms22084190.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jorgovanovic D, Song M, Wang L, Zhang Y. Roles of IFN-γ in tumor progression and regression: a review. Biomark Res. 2020;8:49. https://doi.org/10.1186/s40364-020-00228-x.

Article  PubMed  PubMed Central  Google Scholar 

Gillard AG, Shin DH, Hampton LA, Lopez-Rivas A, Parthasarathy A, Fueyo J, et al. Targeting innate immunity in glioma therapy. Int J Mol Sci. 2024;25:947. https://doi.org/10.3390/ijms25020947.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koks CA, De Vleeschouwer S, Graf N, Van Gool SW. Immune suppression during oncolytic virotherapy for high-grade glioma; yes or no? J Cancer. 2015;6:203–17. https://doi.org/10.7150/jca.10640.

Article  PubMed  PubMed Central  Google Scholar 

Wang X, Shen Y, Wan X, Hu X, Cai WQ, Wu Z, et al. Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy. J Transl Med. 2023;21:500. https://doi.org/10.1186/s12967-023-04360-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Müller L, Berkeley R, Barr T, Ilett E, Errington-Mais F. Past, present and future of oncolytic reovirus. Cancers (Basel). 2020;12:3219. https://doi.org/10.3390/cancers12113219.

Article  CAS  PubMed  Google Scholar 

留言 (0)

沒有登入
gif